Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of “Buy” by Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $10.00.

RVPH has been the topic of several research reports. HC Wainwright cut their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. Roth Mkm assumed coverage on Reviva Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $7.00 target price for the company. D. Boral Capital reissued a “buy” rating and set a $8.00 price target on shares of Reviva Pharmaceuticals in a research report on Thursday. Finally, Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research note on Friday, January 10th.

Reviva Pharmaceuticals Stock Performance

Shares of NASDAQ RVPH opened at $0.86 on Monday. Reviva Pharmaceuticals has a fifty-two week low of $0.49 and a fifty-two week high of $4.28. The company has a market cap of $39.97 million, a PE ratio of -0.77 and a beta of 0.05. The business has a 50-day simple moving average of $1.00 and a two-hundred day simple moving average of $1.38.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its earnings results on Monday, March 31st. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. On average, sell-side analysts predict that Reviva Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several institutional investors have recently made changes to their positions in RVPH. Geode Capital Management LLC grew its position in Reviva Pharmaceuticals by 11.9% during the fourth quarter. Geode Capital Management LLC now owns 311,701 shares of the company’s stock valued at $564,000 after buying an additional 33,205 shares during the period. Tang Capital Management LLC purchased a new position in shares of Reviva Pharmaceuticals in the 4th quarter valued at about $308,000. Ameriprise Financial Inc. acquired a new position in Reviva Pharmaceuticals in the 4th quarter worth about $84,000. EMC Capital Management boosted its position in Reviva Pharmaceuticals by 142.0% during the fourth quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after purchasing an additional 26,134 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Reviva Pharmaceuticals by 848.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock valued at $48,000 after purchasing an additional 23,953 shares during the period. 63.18% of the stock is owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.